COMPANY PROFILE // THE 014 REPORT
Syndax Pharmaceuticals Inc
SNDX (Nasdaq)
Assembled from 5 government sources in 0.2 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- AmberLEI 529900OF94TRHKZVBS87 registration status is LAPSED (last update 2021-07-19): the legal-entity record has not been renewed.
- InfoGLEIF: no direct parent reported; reporting exception reason NO_KNOWN_PERSON.
✓ SEC filings✓ LEI✓ State registrationpossible match✗ SAM registration✗ IRS return✗ Website✗ Lobbying registration
No SAM registration, no IRS return, no website, no lobbying registration on record.
Syndax Pharmaceuticals Inc is an SEC-registered operating company in pharmaceutical preparations, incorporated in DE, based in New York, NY; listed as SNDX (Nasdaq).[source] It reported revenue of $172.4 million for the fiscal year ended 2025-12-31.[source] It has filed 55 documents with the SEC in the last 12 months; the latest is Form 4, filed 2026-11-12.[source] Its largest institutional holders on 13F filings are BlackRock, Inc., Kynam Capital Management, LP, GOLDMAN SACHS GROUP INC (as of 2026-06-30).[source] Seraphix flags 1 item from these records: LEI 529900OF94TRHKZVBS87 registration status is LAPSED (last update 2021-07-19).[source]
- red0
- amber1
- info1
- BlackRock, Inc.$197.2M
- Kynam Capital Management, LP$176.0M
- GOLDMAN SACHS GROUP INC$128.1M
- STATE STREET CORP$123.7M
- BANK OF AMERICA CORP /DE/$88.4M
- VANGUARD CAPITAL MANAGEMENT LLC$85.9M
- DEERFIELD MANAGEMENT COMPANY, L.P.$82.6M
- Eversept Partners, LP$61.2M
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Botwood Nicholas A.J. · Head of R&D, CMO (Officer) · latest Form 4 2026-02-06 · filing · LinkedIn search
- Goldan Keith A. · Chief Financial Officer (Officer) · latest Form 4 2026-02-10 · filing · LinkedIn search
- Metzger Michael A · Chief Executive Officer (Director,Officer) · latest Form 4 2026-02-10 · filing · LinkedIn search
- Huber Martin H. Jr. · Director · latest Form 4 2026-02-06 · filing · LinkedIn search
- Jarrett Jennifer · Director · latest Form 4 2026-02-06 · filing · LinkedIn search
- Katkin Keith · Director · latest Form 4 2026-02-06 · filing · LinkedIn search
- Legault Pierre · Director · latest Form 4 2026-02-06 · filing · LinkedIn search
- Podlesak Dennis · Director · latest Form 4 2026-02-06 · filing · LinkedIn search
- Rizo Aleksandra · Director · latest Form 4 2026-02-06 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
Legal counsel, as publicly named
- Jaime L. Chase Jaime L. Chase Cooley LLP · Exhibit 5.1 legal opinion, S-8 filed 2026-02-26
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 25 CLEAR, 1 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001395937 | source |
| LEI | 529900OF94TRHKZVBS87 | source |
| EIN | 32-0162505 | source |
| NY DOS ID | 4864527 | record |
| Business address (SEC) | 730 THIRD AVENUE, NEW YORK, NY, 10017 | source |
Does not exist in the records we hold: UEI, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2020-01-02 · in -2,515 days · LEI next renewal (529900OF94TRHKZVBS87)
- 2027-03-01 · in 100 days · Next 10-K due (period ended 2026-12-31; Large accelerated filer) (computed from the fiscal year end and filer status)
- 2027-05-10 · in 170 days · Next 10-Q due (period ended 2027-03-31; Large accelerated filer) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
ADDRESS · ZIP CODE
Location context
At the same address (2)
- FRESH CONNECTIONS NYC INC · IRS-registered organization
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- Pyxis Oncology, Inc. · Metzger Michael A
- Sagimet Biosciences Inc. · Jarrett Jennifer
- Arcus Biosciences, Inc. · Jarrett Jennifer
- Zura Bio Ltd · Jarrett Jennifer
- Emergent BioSolutions Inc. · Katkin Keith
- Eledon Pharmaceuticals, Inc. · Katkin Keith
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-02 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-02 officer change 8-K items 2.02,5.02,9.01 · SEC EDGAR
- 2026-10-29 filing 144 · SEC EDGAR
- 2026-08-04 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-04 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-07-14 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-07-08 filing 144 · SEC EDGAR
- 2026-06-12 filing 144 · SEC EDGAR
- 2026-06-11 filing 144 · SEC EDGAR
- 2026-06-10 filing 8-K items 1.01,2.03,3.02,9.01 · SEC EDGAR
- 2026-06-10 officer change 8-K items 5.02,5.07,9.01 · SEC EDGAR
- 2026-06-04 filing DEFA14A · SEC EDGAR
- 2026-06-04 filing 8-K items 1.01,2.03,3.02,8.01,9.01 · SEC EDGAR
- 2026-06-01 filing 144 · SEC EDGAR
- 2026-06-01 filing 144 · SEC EDGAR
- 2026-04-30 filing ARS · SEC EDGAR
- 2026-04-30 filing DEFA14A · SEC EDGAR
- 2026-04-30 filing Proxy statement · SEC EDGAR
- 2026-04-30 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-04-30 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-02-26 filing S-8 · SEC EDGAR
- 2026-02-26 filing Annual report (10-K) · SEC EDGAR
- 2026-02-26 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-02-09 filing 144 · SEC EDGAR
- 2026-02-09 filing 144 · SEC EDGAR
- 2026-02-06 filing 144 · SEC EDGAR
- 2026-02-06 filing 144 · SEC EDGAR
- 2026-02-06 insider First Form 3/4/5 on record for Jarrett Jennifer (Director) · SEC Forms 3/4/5
- 2026-02-06 insider First Form 3/4/5 on record for Legault Pierre (Director) · SEC Forms 3/4/5
- 2026-02-06 insider First Form 3/4/5 on record for Rizo Aleksandra (Director) · SEC Forms 3/4/5
156 earlier entries
- 2026-01-12 filing 8-K items 2.02,7.01
- 2025-12-19 filing 8-K items 5.03
- 2025-11-03 filing Quarterly report (10-Q)
- 2025-11-03 filing 8-K items 2.02,9.01
- 2025-10-24 filing 8-K items 8.01,9.01
- 2025-09-08 filing 144
- 2025-08-18 filing 144
- 2025-08-18 insider First Form 3/4/5 on record for Podlesak Dennis (Director)
- 2025-08-14 filing 144
- 2025-08-04 filing Quarterly report (10-Q)
- 2025-08-04 filing 8-K items 2.02,9.01
- 2025-07-18 insider First Form 3/4/5 on record for Metzger Michael A (Chief Executive Officer)
- 2025-07-16 filing 144
- 2025-07-16 filing 144
- 2025-07-10 filing 144
- 2025-06-26 officer change 8-K items 5.02
- 2025-05-19 insider First Form 3/4/5 on record for Goldan Keith A. (Chief Financial Officer)
- 2025-05-19 insider First Form 3/4/5 on record for Huber Martin H. Jr. (Director)
- 2025-05-19 insider First Form 3/4/5 on record for Katkin Keith (Director)
- 2025-05-16 officer change 8-K items 5.02,7.01,9.01
- 2025-05-16 insider First Form 3/4/5 on record for Botwood Nicholas A.J. (Head of R&D, CMO)
- 2025-05-05 filing Quarterly report (10-Q)
- 2025-05-05 filing 8-K items 2.02,8.01,9.01
- 2025-04-01 filing ARS
- 2025-04-01 filing DEFA14A
- 2025-04-01 filing Proxy statement
- 2025-03-04 filing 144
- 2025-03-04 filing S-8
- 2025-03-03 filing Annual report (10-K)
- 2025-03-03 filing 8-K items 2.02,8.01,9.01
- 2025-02-10 filing 144
- 2025-02-10 filing 144
- 2025-02-10 filing 144
- 2024-12-20 officer change 8-K items 5.02
- 2024-11-18 filing 8-K items 8.01,9.01
- 2024-11-12 filing 8-K items 8.01,9.01
- 2024-11-05 filing Quarterly report (10-Q)
- 2024-11-05 filing 8-K items 2.02,9.01
- 2024-11-04 filing 8-K items 1.01
- 2024-08-01 filing Quarterly report (10-Q)
- 2024-08-01 filing 8-K items 2.02,9.01
- 2024-05-15 officer change 8-K items 5.02,5.07,7.01,9.01
- 2024-05-08 filing Quarterly report (10-Q)
- 2024-05-08 filing 8-K items 2.02,9.01
- 2024-04-02 filing ARS
- 2024-04-02 filing DEFA14A
- 2024-04-02 filing Proxy statement
- 2024-03-18 officer change 8-K items 5.02,7.01,9.01
- 2024-02-27 filing S-3ASR
- 2024-02-27 filing S-8
- 2024-02-27 filing Annual report (10-K)
- 2024-02-27 filing 8-K items 2.02,9.01
- 2023-12-20 filing 8-K items 8.01,9.01
- 2023-12-15 filing 8-K items 1.01,9.01
- 2023-12-15 filing 424B5
- 2023-12-14 filing 424B5
- 2023-12-12 filing 8-K items 8.01,9.01
- 2023-12-07 filing UPLOAD
- 2023-11-28 filing CORRESP
- 2023-11-13 filing UPLOAD
- 2023-11-02 filing Quarterly report (10-Q)
- 2023-11-02 filing 8-K items 2.02,9.01
- 2023-10-02 filing 8-K items 8.01,9.01
- 2023-08-09 filing 144
- 2023-08-03 filing Quarterly report (10-Q)
- 2023-08-03 filing 8-K items 2.02,9.01
- 2023-08-02 filing 144
- 2023-07-24 filing 8-K items 8.01,9.01
- 2023-07-10 filing 144
- 2023-06-09 filing 144
- 2023-05-26 filing 8-K items 1.02,8.01,9.01
- 2023-05-26 filing 424B5
- 2023-05-18 filing 8-K items 3.03,5.03,5.07,9.01
- 2023-05-09 filing 144
- 2023-05-08 filing Quarterly report (10-Q)
- 2023-05-08 officer change 8-K items 2.02,5.02,9.01
- 2023-04-18 filing DEFA14A
- 2023-04-07 filing ARS
- 2023-04-07 filing DEFA14A
- 2023-04-07 filing Proxy statement
- 2023-03-30 officer change 8-K items 5.02,7.01,9.01
- 2023-03-28 filing PRE 14A
- 2023-02-28 filing S-8
- 2023-02-28 filing Annual report (10-K)
- 2023-02-28 filing 8-K items 2.02,9.01
- 2023-02-08 officer change 8-K items 5.02,9.01
- 2022-12-14 filing 8-K items 2.02,7.01,9.01
- 2022-12-07 filing 8-K items 1.01,9.01
- 2022-12-07 filing 424B5
- 2022-12-06 filing 424B5
- 2022-12-05 officer change 8-K items 5.02,9.01
- 2022-11-03 filing Quarterly report (10-Q)
- 2022-11-03 filing 8-K items 2.02,9.01
- 2022-09-23 filing 8-K items 1.02,7.01,9.01
- 2022-08-08 filing Quarterly report (10-Q)
- 2022-08-08 filing 8-K items 2.02,9.01
- 2022-06-13 officer change 8-K items 5.02,9.01
- 2022-05-11 filing 8-K items 5.07,9.01
- 2022-05-09 filing 8-K items 2.02,9.01
- 2022-05-09 filing Quarterly report (10-Q)
- 2022-03-30 filing DEFA14A
- 2022-03-29 filing Proxy statement
- 2022-03-04 filing SC 13D/A
- 2022-03-01 filing S-8
- 2022-03-01 filing Annual report (10-K)
- 2022-03-01 officer change 8-K items 2.02,5.02,7.01,9.01
- 2022-02-24 officer change 8-K items 5.02,9.01
- 2022-02-03 officer change 8-K items 5.02,7.01,9.01
- 2021-12-23 filing 8-K items 1.01,2.03,9.01
- 2021-12-17 filing 8-K items 1.01,9.01
- 2021-12-17 filing 424B5
- 2021-12-16 filing 424B5
- 2021-12-13 filing 8-K items 8.01,9.01
- 2021-12-09 filing 8-K items 8.01,9.01
- 2021-12-09 filing 424B5
- 2021-11-15 filing Quarterly report (10-Q)
- 2021-11-15 filing 8-K items 2.02,9.01
- 2021-10-04 officer change 8-K items 5.02,9.01
- 2021-09-27 filing 8-K items 1.01,7.01,9.01
- 2021-09-15 officer change 8-K items 5.02,9.01
- 2021-08-09 filing Quarterly report (10-Q)
- 2021-08-09 filing S-8
- 2021-08-09 filing 8-K items 2.02,9.01
- 2021-05-13 filing 8-K items 5.07
- 2021-05-11 filing Quarterly report (10-Q)
- 2021-05-11 filing 8-K items 2.02,9.01
- 2021-05-03 filing SC 13D
- 2021-04-30 filing 10-K/A
- 2021-04-01 filing Proxy statement
- 2021-03-24 filing S-3ASR
- 2021-03-24 filing RW
- 2021-03-22 filing S-3
- 2021-03-12 filing Annual report (10-K)
- 2021-03-08 filing 8-K items 2.02,9.01
- 2021-02-05 officer change 8-K items 5.02
- 2020-12-09 filing 8-K items 1.01,9.01
- 2020-12-09 filing 424B5
- 2020-12-07 filing 8-K items 1.02,8.01,9.01
- 2020-12-07 filing 424B5
- 2020-11-05 filing Quarterly report (10-Q)
- 2020-11-02 filing 8-K items 2.02,9.01
- 2020-08-06 filing Quarterly report (10-Q)
- 2020-08-06 filing S-8
- 2020-08-06 filing 8-K items 2.02,9.01
- 2020-07-07 officer change 8-K items 5.02,9.01
- 2020-06-09 filing 8-K items 5.07
- 2020-05-07 filing Quarterly report (10-Q)
- 2020-05-07 filing 8-K items 2.02,9.01
- 2020-05-04 filing 8-K items 1.01,8.01,9.01
- 2020-05-04 filing 424B5
- 2020-04-30 filing 8-K items 2.02,8.01,9.01
- 2020-04-30 filing 424B5
- 2020-04-29 filing Proxy statement
- 2020-03-05 filing Annual report (10-K)
- 2020-03-03 filing 8-K items 2.02,9.01
- 2020-02-20 officer change 8-K items 5.02
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-02 (within 30 days) 10-Q filed
- 2026-11-02 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 5.02 officer or director change; Item 9.01 exhibits
- 2026-08-04 (older) 10-Q filed
- 2026-08-04 (older) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-07-21 (older) Form 5500 received for plan year ending 2025-12-31 (plan no. 001)
- 2026-07-14 (older) 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-06-10 (older) 8-K filed: Item 1.01 material agreement; Item 2.03 new financial obligation; Item 3.02 unregistered equity sale; Item 9.01 exhibits
- 2026-06-10 (older) 8-K filed: Item 5.02 officer or director change; Item 5.07 shareholder vote; Item 9.01 exhibits
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-21; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:SNDX The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
6 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1395937 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | SNDX / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| LEI (root of the ownership tree) | 529900OF94TRHKZVBS87 | id:lei-family: legal entity in this company's GLEIF ownership tree (LEI 529900OF94TRHKZVBS87) | GLEIF |
| EIN | 320162505 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001395937 | SEC EDGAR / IRS |
| CUSIP | 87164F105 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001395937 | SEC EDGAR |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2025-12-31) | $172,352,000 | 2025-12-31 | 10-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax | as filed | 2026-11-21 11:30 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | -$285,422,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-21 11:30 UTC | Report an error |
| Total assets (at 2025-12-31) | $529,706,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-21 11:30 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $64,630,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-21 11:30 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $134,930,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-21 11:30 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-12 | SEC EDGAR company profile | as filed | 2026-11-21 11:30 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-12 | SEC EDGAR company profile | as filed | 2026-11-21 11:30 UTC | Report an error |
| State of incorporation | DE | 2026-11-12 | SEC EDGAR company profile | as filed | 2026-11-21 11:30 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-12 | SEC EDGAR company profile | as filed | 2026-11-21 11:30 UTC | Report an error |
| Business address | 730 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, 10017 | 2026-11-12 | SEC EDGAR company profile | as filed | 2026-11-21 11:30 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-12 | SEC EDGAR company profile | as filed | 2026-11-21 11:30 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$322,980,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-21 11:30 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $187,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-21 11:30 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $1,521,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-21 11:30 UTC | Report an error |
| Form D total offering amount (D filed 2015-08-28) | $61,252,462 | 2015-08-28 | D | as filed | 2026-11-21 11:30 UTC | Report an error |
| Form D total amount sold (D filed 2015-08-28) | $61,252,462 | 2015-08-28 | D | as filed | 2026-11-21 11:30 UTC | Report an error |
| Form D industry group | Pharmaceuticals | 2015-08-28 | D | as filed | 2026-11-21 11:30 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2015-08-28 | D | as filed | 2026-11-21 11:30 UTC | Report an error |
| Form D date of first sale | 2015-08-21 | 2015-08-28 | D | as filed | 2026-11-21 11:30 UTC | Report an error |
| Plan (pension, plan no. 001) | SYNDAX PHARMACEUTICALS, INC. 401(K) PLAN: 354 participants, assets $38,504,421 | 2025-12-31 | DOL EBSA Form 5500 public datasets (dataset) | as filed | 2026-11-21 11:30 UTC | Report an error |
| Plan (welfare, plan no. 501) | SYNDAX PHARMACEUTICALS HEALTH & WELFARE BENEFITS PLAN: 536 participants | 2025-12-31 | DOL EBSA Form 5500 public datasets (dataset) | as filed | 2026-11-21 11:30 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-02 · accession 0001193125-26-443625
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Revenue | $83,298,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-02 | 0001193125-26-443625 | 2026-11-21 11:30 UTC | Report an error |
| Net income (loss) | -$49,433,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-02 | 0001193125-26-443625 | 2026-11-21 11:30 UTC | Report an error |
| Interest expense | $2,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-02 | 0001193125-26-443625 | 2026-11-21 11:30 UTC | Report an error |
| Cash and cash equivalents | $135,941,000 | at 2026-09-30 | 10-Q | 2026-11-02 | 0001193125-26-443625 | 2026-11-21 11:30 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-02 Filing 10-Q filed
- 2026-11-02 Filing 8-K filed: Item 2.02 results of operations; Item 5.02 officer or director change; Item 9.01 exhibits
- 2026-08-04 Filing 10-Q filed
- 2026-08-04 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-07-21 Filing Form 5500 received for plan year ending 2025-12-31 (plan no. 001)
- 2026-07-14 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-06-10 Filing 8-K filed: Item 1.01 material agreement; Item 2.03 new financial obligation; Item 3.02 unregistered equity sale; Item 9.01 exhibits
- 2026-06-10 Filing 8-K filed: Item 5.02 officer or director change; Item 5.07 shareholder vote; Item 9.01 exhibits
- 2026-06-09 Filing Form 5500 received for plan year ending 2025-12-31 (plan no. 501)
- 2026-06-04 Filing DEFA14A filed
- 2026-06-04 Filing 8-K filed: Item 1.01 material agreement; Item 2.03 new financial obligation; Item 3.02 unregistered equity sale; Item 8.01 other event; Item 9.01 exhibits
- 2026-04-30 Filing ARS filed
- 2026-04-30 Filing DEFA14A filed
- 2026-04-30 Filing DEF 14A filed
- 2026-04-30 Filing 10-Q filed
- 2026-04-30 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-04-20 Record earliest certified decision date in the file
- 2026-04-20 Record latest certified decision date in the file
- 2026-02-26 Filing S-8 filed
- 2026-02-26 Filing 10-K filed
- 2026-02-26 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-01-12 Filing 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure
- 2025-12-19 Filing 8-K filed: Item 5.03 charter or bylaw amendment
- 2025-11-03 Filing 10-Q filed
- 2025-11-03 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
6 earlier entries
- 2025-10-24 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2025-08-04 Filing 10-Q filed
- 2025-08-04 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2025-06-26 Filing 8-K filed: Item 5.02 officer or director change
- 2024-01-01 Record plan effective date: SYNDAX PHARMACEUTICALS HEALTH & WELFARE BENEFITS PLAN
- 2007-01-01 Record plan effective date: SYNDAX PHARMACEUTICALS, INC. 401(K) PLAN
8-K item text, as filed (excerpts)
- 2026-11-02 8-K Item 2.02, Results of Operations and Financial Condition
On November 2, 2026, Syndax Pharmaceuticals, Inc. (the “Company”) issued a press release and presentation announcing its financial results for the quarter ended September 30, 2026. A copy of the press release and presentation are furnished as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and are incorporated herein by reference. The information contained in this Item 2.02 and in Exhibits 99.1 and 99.2 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference… the 8-K · retrieved 2026-11-21 11:30 UTC - 2026-08-04 8-K Item 2.02, Results of Operations and Financial Condition
On August 4, 2026, Syndax Pharmaceuticals, Inc. (the “Company”) issued a press release and presentation announcing its financial results for the quarter and year ended June 30, 2026. A copy of the press release and presentation are furnished as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and are incorporated herein by reference. The information contained in this Item 2.02 and in Exhibits 99.1 and 99.2 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by… the 8-K · retrieved 2026-11-21 11:30 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
POSSIBLE MATCHES · GROUPED BY SOURCE8. Enforcement by agency
Breach states (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchSyndax Pharmaceuticals, Inc. · exact legal name · sx:brst:md:ITU-374357-aad4d3 Compare
Each record's own page holds its date and the agency document. Matched by exact name only; none of these is counted in the headline.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | $197,177,353 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:30 UTC | Report an error |
| 2 | Kynam Capital Management, LP | $175,993,964 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:30 UTC | Report an error |
| 3 | GOLDMAN SACHS GROUP INC | $128,127,253 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:30 UTC | Report an error |
| 4 | STATE STREET CORP | $123,693,149 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:30 UTC | Report an error |
| 5 | BANK OF AMERICA CORP /DE/ | $88,425,755 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:30 UTC | Report an error |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | $85,863,719 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:30 UTC | Report an error |
| 7 | DEERFIELD MANAGEMENT COMPANY, L.P. | $82,628,614 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:30 UTC | Report an error |
| 8 | Eversept Partners, LP | $61,168,871 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:30 UTC | Report an error |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | $56,499,563 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:30 UTC | Report an error |
| 10 | Hood River Capital Management LLC | $56,055,139 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:30 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
GLEIF OWNERSHIP TREE · ID TIER11. Subsidiaries
1 legal entity in the company's GLEIF ownership tree, joined by LEI (an official identifier).
- SYNDAX PHARMACEUTICALS, INC. · LEI 529900OF94TRHKZVBS87 · root
Exhibit 21 subsidiaries: not held yet.
DOL H-1B (LCA) · WARN NOT HELD12. Labor
| Measure | Value | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|
| Employer name (as filed) | Syndax Pharmaceuticals, Inc | 2026-06-30 | DOL OFLC LCA Disclosure Data (dataset) | 2026-11-21 11:30 UTC | Report an error |
| Certified LCAs | 1 | 2026-06-30 | DOL OFLC LCA Disclosure Data (dataset) | 2026-11-21 11:30 UTC | Report an error |
| Certified LCAs later withdrawn | 0 | 2026-06-30 | DOL OFLC LCA Disclosure Data (dataset) | 2026-11-21 11:30 UTC | Report an error |
| Total worker positions on certified LCAs | 1 | 2026-06-30 | DOL OFLC LCA Disclosure Data (dataset) | 2026-11-21 11:30 UTC | Report an error |
| Top job titles (title, LCA count) | Director, IT R&D Technology Platforms and Operations (1) | 2026-06-30 | DOL OFLC LCA Disclosure Data (dataset) | 2026-11-21 11:30 UTC | Report an error |
| Wage offered, annualized (n, min, median, max) | median $220,000 (range $220,000-$220,000, 1 filings) | 2026-06-30 | DOL OFLC LCA Disclosure Data (dataset) | 2026-11-21 11:30 UTC | Report an error |
| Worksite states | NC | 2026-06-30 | DOL OFLC LCA Disclosure Data (dataset) | 2026-11-21 11:30 UTC | Report an error |
Unconfirmed: these labor figures (positions, worksite states, certified LCAs later withdrawn) are as read from DOL's quarterly LCA disclosure file. Seraphix's independent second check of them is not finished (11-19); they are shown as filed, not as verified.
WARN layoff notices: not held yet.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
5 state and city records carry this company's exact name, from 3 sources. Possible matches only.
State licences (3)
possible match: matched by name only, not merged (3)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchSYNDAX PHARMACEUTICALS INC · exact legal name · sx:elic:ctcred:2630667 Compare
- possible matchSYNDAX PHARMACEUTICALS, INC. · exact legal name · sx:elic:ctcred:1749664 Compare
- possible matchSyndax Pharmaceuticals, Inc. · exact legal name · sx:elic:ctcred:2666639 Compare
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchSyndax Pharmaceuticals · exact name match to 'Syndax Pharmaceuticals Inc' (no other entity shares the name) · sx:ctgov:h984a6e59e985d431 Compare
New York corporations (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchSYNDAX PHARMACEUTICALS, INC. · exact legal name · sx:nydos:4864527 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1395937.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001395937. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.